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Pancreatic sympathetic nerves contribute to increased 
glucagon secretion during severe hypoglycemia in dogs 
PETER J. HAVEL, THOMAS 0. MUNDINGER, AND GERALD J. TABORSE(Y, JR. 
Department of Anatomy, Physiology, and Cell Biology, School of Veterinary Medicine and 
Department of Nutrition, University of California, Davis, California 95616; and Department of 
Medicine, University of Washington and Veterans Affairs Medical Center, 
Seattle, Washington 98108 
Havel, Peter J., Thomas 0. Mundinger, and Gerald J. 
Taborsky, Jr. Pancreatic sympathetic nerves contribute to 
increased glucagon secretion during severe hypoglycemia in 
dogs. Am. J. Physiol. 270 (Endocrinol. Metab. 33): E20-E26, 
1996.-To determine if pancreatic sympathetic nerves can 
contribute to increased glucagon secretion during hypoglyce- 
mia, plasma glucagon and pancreatic glucagon secretion in 
situ were measured before and during insulin-induced hypo- 
glycemia in three groups of halothane-anesthetized dogs. All 
dogs were bilaterally vagotomized to eliminate the input from 
pancreatic parasympathetic nerves. One group of dogs re- 
ceived only vagotomy (VAGX). A second group was vagoto- 
mized and adrenalectomized (VAGX + ADX). A third group 
received vagotomy, adrenalectomy, plus surgical denervation 
of the pancreas (VAGX + ADX + NERVX) to prevent activa- 
tion of pancreatic sympathetic nerves. In dogs with VAGX 
only, hypoglycemia increased plasma epinephrine (Epi), pan- 
creatic norepinephrine (NE) output (+320 2 140 pg/min, 
P < 0.05), arterial plasma glucagon (+28 t 12 pg/ml, 
P < O.Ol), and pancreatic glucagon output (+ 1,470 k 370 
pg/min, P < 0.01). The addition of ADX eliminated the in- 
crease of Epi but did not increase pancreatic NE output 
(+370 -+ 190 pg/min, P < 0.025), arterial plasma glucagon 
(+20 t 5 pg/ml, P < O.Ol>, or pancreatic glucagon output 
(+810 t 200 pg/min, P < 0.01). In contrast, the addition of 
pancreatic denervation eliminated the increase of pancreatic 
NE output (-20 2 40 pg/min, P < 0.05 vs. VAGX), the arte- 
rial glucagon (+ 1 t 2 pg/ml, P < 0.01 vs. VAGX), and pancre- 
atic glucagon output responses (+210 2 280 pg/min, P -=c 0.025 
vs. VAGX) to hypoglycemia. Thus activation of pancreatic 
sympathetic nerves can contribute to the increased glucagon 
secretion during severe insulin-induced hypoglycemia in dogs. 
epinephrine; norepinephrine; vagotomy; adrenalectomy; pan- 
creatic denervation 
INCREASED GLUCAGON Secretion is a primary COunterregu- 
latory factor in the recovery of plasma glucose levels 
from insulin-induced hypoglycemia (10, 15). However, 
the question of which mechanisms are responsible for 
stimulating glucagon secretion during hypoglycemia 
remains controversial. For example, hypoglycemia per 
se could directly increase glucagon secretion because 
lowered glucose concentrations increase glucagon secre- 
tion from isolated perfused pancreas preparations (41) 
and from isolated islets (32). However, the pancreas 
also receives three different autonomic inputs: 1) pan- 
creatic parasympathetic nerves, 2) the circulating neu- 
rohormone, epinephrine, and 3) pancreatic sympa- 
thetic nerves. 
Activation of the adrenal medulla during hypoglyce- 
mia was first demonstrated by Cannon more than 70 
years ago (8). Adrenal epinephrine release is centrally 
mediated via the splanchnic sympathetic nerves. The 
activation of pancreatic parasympathetic nerves dur- 
ing hypoglycemia has been inferred by increases of 
plasma pancreatic polypeptide, a hormone secreted by 
the islet F cells, which is known to be under strong 
vagal control (21, 38). More recently, we have demon- 
strated that the sympathetic nerves of the pancreas are 
activated during central neuroglucopenia (25) and insu- 
lin-induced hypoglycemia (19). Although activation of 
each of these autonomic inputs to the pancreas has 
been demonstrated to stimulate glucagon secretion in 
the absence of hypoglycemia (2, 3, 5, 11, 16, 28>, it has 
been difficult to determine the contribution of the 
autonomic nervous system in mediating increases of 
plasma glucagon during hypoglycemia. This difficulty 
may be due, in part, to redundancy between the three 
autonomic inputs to pancreas in stimulating A cell 
glucagon secretion during hypoglycemia (for reviews 
see Refs. 23 and 24). 
Results of recent studies support the redundancy 
hypothesis. In these experiments, pharmacological 
blockade or ablation of all three autonomic inputs to the 
pancreas markedly reduced the glucagon response to 
hypoglycemia (17,26), whereas in most experiments in 
which only one or two of the autonomic inputs were 
blocked or ablated, there was no major effect on the 
glucagon response (for reviews see Refs. 23 and 33). 
The hypothesis of redundant autonomic mediation of 
glucagon secretion is directly supported by the results 
of a study in which neither methylatropine nor QI- and 
p-adrenergic blockade alone significantly reduced the 
increase of glucagon during insulin-induced hypoglyce- 
mia in conscious rats, but both atropine and adrenergic 
blockade together eliminated 75% of the response (22). 
The goal of this study was to examine the potential 
for the direct sympathetic innervation of the pancreas 
to contribute to increased glucagon secretion during 
insulin-induced hypoglycemia. Because we hypoth- 
esized redundant autonomic mediation of the glucagon 
response to hypoglycemia, the autonomic inputs to the 
pancreas were sequentially ablated, concluding with 
ablation of the sympathetic innervation of the pan- 
creas. Thus the first group of dogs served as a control 
group and received vagotomy alone (VAGX). The second 
group of dogs was vagotomized and the adrenal glands 
were removed bilaterally to prevent the release of 
adrenal medullary epinephrine (VAGX + ADX). Last, 
to determine the contribution of the pancreatic sympa- 
thetic nerves to the A cell secretory responses to 
hypoglycemia in the absence of parasympathetic and 
adrenal medullary activation, a third group of dogs was 
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vagotomized, adrenalectomized, and the entire pancreas 
was surgically denervated (VAGX + ADX + NERm). Ar- 
terial plasma glucagon responses and glucagon secre- 
tion from the pancreas in situ were measured in the 
three groups of dogs. Norepinephrine output or spill- 
over from noradrenergic nerves in the in situ pancreas 
was measured to assess the activation of pancreatic 
sympathetic nerves during hypoglycemia in the first 
two groups of dogs and the effectiveness of the pancre- 
atic denervation procedure in the third group of ani- 
mals. 
RESEARCH DESIGN AND METHODS 
Animals and surgical procedures. Adult dogs of mixed 
breed weighing 24-40 kg were used for these studies. After an 
overnight fast (-18 h), anesthesia was induced with thiamy- 
la1 sodium (Surital, Parke Davis, Morris Plains, NJ). Anesthe- 
sia was subsequently maintained with halothane (0.8%) 
administered from a calibrated vaporizer (Draeger, Germany) 
by mechanical ventilation in 100% oxygen. This anesthetic 
regimen was chosen because it provides full surgical anesthe- 
sia but does not suppress parasympathetic or sympathoadre- 
nal activation induced by neuroglucopenic stress, as do some 
other anesthetics, e.g., pentobarbital(18,20). 
To access pancreatic venous blood, a laparotomy was 
performed and an extracorporeal Silastic (Dow Corning, 
Midland, MI) shunt containing a sampling port, an ultrasonic 
flow probe (Transonic Systems, Ithaca, NY), and a heparin 
infusion line, was placed between the superior pancreaticoduo- 
denal vein (SPDV) and the portal vein. This procedure allows 
the measurement of hormone output (26) and neurotransmit- 
ter spillover (19,26) from the right lobe (duodenal region and 
uncinate process) of the pancreas (-3550% of the canine 
pancreas). The femoral artery (FA) and vein were cannulated 
for blood sampling and drug infusion, respectively. Saline 
(0.9%) was infused intravenously at a slow rate throughout 
the surgery and the experiments. 
In all dogs, the parasympathetic input to the pancreas was 
surgically ablated by bilateral cervical vagotomy. The right 
and left cervical vagal trunks were dissected free from their 
tracts along the carotid arteries, ligated, and cut (26). One 
group of dogs was vagotomized only. Another group of dogs 
was vagotomized and in addition the right and left adrenal 
glands were surgically removed after ligation of the adrenal 
vasculature and adjacent connective tissue (14). A third group 
of dogs was vagotomized, adrenalectomized, and in addition 
the pancreas was surgically denervated by ligating and 
separating the pancreas and duodenum to the level of the 
pylorus. All of the mesenteric attachments to the pancreas 
were ligated and cut and the nerves fibers around the 
pancreatic blood vessels were dissected free, ligated, and 
severed (25). 
All surgeries and experiments were performed in the 
presence of full surgical anesthesia. These experiments were 
acute, terminal procedures. At the conclusion of the experi- 
mental protocols, each animal used in these studies was 
killed with an intravenous overdose of thiopental sodium 
(Pentothal, Abbott Laboratories, North Chicago, IL), without 
regaining consciousness. 
Hypoglycemia protocol. After the surgical procedures, paired 
blood samples for glucose, catecholamine, and glucagon deter- 
mination were drawn from the femoral artery and from the 
pancreatic venous shunt at -10 and 0 min before insulin 
injection to establish baseline measurements for the subse- 
quent hypoglycemic period. To produce acute marked hypogly- 
cemia, a bolus of regular porcine insulin (Squibb-Novo, 
Bagsvaerd, Denmark) was administered into the femoral vein 
cannula at a dose of 3.0 U/kg. Paired blood samples were 
drawn at 5, 15,30,35,40,45,50,55, and 60 min after insulin 
injection. After 60 min the hypoglycemia was reversed by 
administering glucose (50% solution) intravenously as a bolus 
of 150 mg/kg followed by an infusion of 15 mg. kg-l. min+ to 
equal or exceed baseline arterial glucose levels for 60 min. 
Paired samples were drawn at 5, 15, 30, 45, and 60 min after 
the start of the glucose infusion. In all experiments, blood 
flow in the pancreatic venous shunt was monitored with an 
ultrasonic transit-time flowmeter (Transonic Systems). Hema- 
tocrit was determined at regular intervals throughout the 
experiments. 
Assays. Blood samples for glucose determination were 
drawn and placed in tubes containing EDTA. Blood samples 
for glucagon determination were placed in tubes containing 
heparin and benzamidine HCl. Blood samples for catechol- 
amine determination were placed in tubes containing ethyl- 
ene glycol-bis( P-aminoethyl ether)-N,N,N’,N ‘-tetraacetic acid 
and glutathione. All samples were kept on ice until centrifuga- 
tion (20 min at 4°C). The plasma was decanted and frozen at 
-20°C until assayed. 
Plasma glucose was assayed by the glucose oxidase method 
with a Beckman glucose analyzer (Beckman Instruments, 
Fullerton, CA). Plasma immunoreactive glucagon (IRG) was 
measured radioimmunologically in unextracted plasma with 
an antibody that has high specificity for the COOH-terminal 
portion of the glucagon molecule (39). It has been previously 
demonstrated that extrapancreatic IRG measured with 
COOH-terminal specific antisera does not increase during 
insulin-induced hypoglycemia in dogs (29). Thus measure- 
ments of plasma glucagon made with this assay are a reliable 
index of pancreatic glucagon secretion. Plasma norepineph- 
rine (NE) and epinephrine (Epi) were measured in duplicate 
with a highly sensitive and specific radioenzymatic assay 
(13). The intra- and interassay coefficients of variation for the 
plasma catecholamine assay in this laboratory are 6 and 12%, 
respectively. 
Calculations and data analysis. The changes of arterial 
plasma glucose, arterial plasma Epi, arterial and pancreatic 
venous plasma NE, pancreatic NE output, arterial and 
pancrea .tic venou s glu cagon, and pancreatic glucagon output 
were calculated by subtracting the mean of the -lo- and 
0-min baseline valu .es from the mean of the 45-, 50-, 55-, and 
60-min values after the administration of insulin. 
Circulating NE is extracted by the pancreas (1). Most of the 
neurotransmitter arriving via the arterial circulation does 
not appear in pancreatic venous plasma, and therefore simple 
measurements of arteriovenous (av) concentration differ- 
ences will seriously underestimate pancreatic neurotransmit- 
ter spillover. To correct the av difference for extraction, 
pancreatic NE spillover was calculated as follows 
mE1 SPDV - (arterial contribution to the SPDV level)} 
X SPDV blood flow X (1 - hematocrit) 
where square brackets indicate concentration. The arterial 
contribution to the SPDV level is defined to be the amount of 
neurotransmitter present in SPDV plasma that arrives via 
the arterial circulation and escapes pancreatic extraction. 
Because Epi is extracted at a rate similar to NE (l), Epi 
extraction has been used to estimate the arterial contribution 
to SPDV NE levels when arterial Epi levels are high (11). 
When arterial Epi levels are very low, such as in adrenalecto- 
mized animals, Epi extraction cannot be used as an index of 
NE extraction. Epi extraction during baseline conditions has 
been measured and found to average 64 t 2%, n = 22. We 
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have found that pancreatic Epi extraction increases to 78 t 
I%, n = 35 during insulin-induced hypoglycemia (P < 0.0005 
vs. baseline). Therefore, an extraction rate for NE of 64% was 
used to calculate NE output at time points during the 
baseline period, and an extraction rate of 78% was used 
during hypoglycemia. The arterial contribution to SPDV NE 
levels during the baseline period is calculated as [NE]FA X 
(1 - 0.64). The arterial contribution during insulin-induced 
hypoglycemia is calculated as [NE]FA X (1 - 0.78). Because 
the NE spillover calculation does not account for the majority 
of neuronal NE release that is taken back up by the sympa- 
thetic nerves, pancreatic NE output is an attenuated index of 
the activity of pancreatic noradrenergic nerves and is there- 
fore likely to underestimate pancreatic sympathetic activa- 
tion. 
The pancreatic output of IRG was calculated as 
[IRGI SPDV - [IRG],* X SPDV blood flow X (1 - hematocrit) 
The data in the text, figures, and tables are expressed as 
means t SE. Statistical comparisons of means within a group 
were made with a Wilcoxon signed-rank test. Statistical 
comparisons of means between different groups were made 
with a Kruskal-Wallis test. 
RESULTS 
Arterial plasma glucose. Arterial plasma glucose 
averaged 107 t 3 mg/dl in VAGX dogs and decreased to 
32 t 2 mg/dl after insulin administration. Baseline 
glucose levels were lower in both VAGX + ADX and 
VAGX + ADX + NERVX dogs (P < 0.0005 vs. VAGX) 
and decreased to a lower nadir (15 IT 2 and 13 t 2 
mg/dl, respectively) in these dogs than in dogs with 
VAGX alone (P < 0.0002 vs. VAGX) (Fig. 1). 
Arterial plasma Epi. Baseline arterial plasma Epi 
was 220 t 60 pg/ml in VAGX dogs and increased 
markedly to 2,890 t 400 pg/ml during hypoglycemia 
(A = +2,670 ? 390 pg/ml, P < O.O05).As expected, base- 
line arterial Epi was lower in both VAGX + ADX and 
VAGX + ADX + NERVX dogs averaging 60 ? 20 and 
INSULIN 
NJECTION 
GLUCOSE 
INFUSION 
60 
MINUTES 
Fig. 1. Arterial (A) plasma glucose before and after insulin injection 
and during posthypoglycemia glucose infusion in dogs with vagotomy 
(VAGX; n = 9; 0) dogs with vagotomy + adrenalectomy (VAGX + ADX 
n = 10; 0) and dogs with vagotomy + adrenalectomy + pancreatic 
denervation (VAGX + ADX + NERVX; n = 6; +>. 
GLUCOSE 
INFUSION 
t-- 
60 
MINUTES 
Fig. 2. The change of arterial (A) plasma epinephrine (AEpi) before 
and after insulin injection and during posthypoglycemia glucose 
infusion in dogs with VAGX (n = 9; q ), dogs with VAGX + ADX 
(n = 10; l ), and dogs with VAGX + ADX + NERVX (n = 6; +). 
50 + 10 pgfml respectively (P < 0.05 vs. VAGX). Arte- - ? 
rial plasma Epi did not increase during hypoglycemia 
in either VAGX + ADX or VAGX + ADX + NERVX dogs 
(P < 0.0001 vs. VAGX) (Fig. 2). 
Pancreatic NE output. Baseline pancreatic NE output 
was 420 t 80 pg/min in VAGX dogs. During insulin- 
induced hypoglycemia pancreatic NE output in these ani- 
mals increased to 740 2 200 pg/min (A = +320 t 140 
pglmin, P < 0.05). Although baseline pancreatic NE 
output was lower in both VAGX + ADX and VAGX + 
ADX + NERVX dogs (P < 0.0025 vs. VAGX) (Table l), 
pancreatic NE output increased to a similar degree 
during hypoglycemia in VAGX + ADX dogs (A = 
+370 t 190 pg/min, P < 0.0125). Pancreatic NE output 
did not increase during hypoglycemia in VAGX + 
ADX + NERVX dogs (A = -20 t 40 pg/min, P < 0.05 
vs. VAGX or VAGX + ADX dogs) (Table 1 and Fig. 3). 
Arterial plasma IRG and pancreatic IRG output. 
Baseline arterial plasma IRG was 25 t 3 pg/ml and 
increased to 53 * 12 pg/ml in VAGX dogs (A = +28 -+ 12 
pg/ml, P < 0.01). Arterial plasma IRG increased by a 
similar amount in VAGX + ADX dogs (A = +20 t 6 
pg/ml, P < 0.01) but did not increase during hypoglyce- 
mia in VAGX + ADX + NERVX dogs (A = +l t 2 
pg/ml, P < 0.01 vs. VAGX or VAGX + ADX dogs) (Table 
2) 
*Pancreatic IRG output increased from 260 t 40 
pg/min to 1,730 t 380 pg/min during hypoglycemia in 
VAGX dogs (A = +1,470 t 370 pg/min, P < 0.01). The 
increase of pancreatic IRG output in VAGX + ADX dogs 
(A = +810 ? 200 pg/min, P < 0.01) was not signifi- 
cantly reduced from the response in dogs with VAGX 
only. In contrast, pancreatic IRG output did not in- 
crease significantly during hypoglycemia in VAGX + 
ADX + NERVX dogs (A = +210 2 280 pg/min, 
P < 0.025 vs. VAGX) (Table 2 and Fig. 4). 
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Table 1. Plasma NE levels and pancreatic NE output before and during hypoglycemia 
P&n1 
Treatment n NEFA NE SPDV BFSPDV, ml/min NE Output, pg/min 
VAGX 
Baseline 
During IIH 
A 
VAGX + ADX 
Baseline 
During IIH 
A 
VAGX + ADX + NERVX 
Baseline 
During IIH 
A 
9 
150 + 30 
790 + 110 
+640t 100* -t 
10 
80220 
3202 100 
+240+90*-f 
6 
50+10 
140 + 50 
+90*4o*"r 
120 + 20 
290 + 50 
-170+50* 
60510 10.5 5 0.8 
150 2 30 10.7 2 1.3 
+90230* +0.2tl.4 
40210 8.020.9 90530 
40210 6.7kO.8 70220 
O-tlOj- - 1.3 + 0.2* -2Ot40T 
10.0 + 1.1 
10.1 k 1.3 
+O.l+ 1.0 
420 k 80 
740 + 200 
+320 2 140* 
160 + 30 
530 5 180 
+370 t 190* 
Values during hypoglycemia are means + SE, 45-60 min postinsulin injection; n, no. of dogs. VAGX, vagotomy; ADX, adrenalectomy; 
NERVX, denervation; IIH, insulin-induced hypoglycemia; NE, norepinephrine FA, femoral artery; SPDV, superior pancreaticoduodenal vein; 
BF, blood flow. *P -=c 0.05 vs. baseline. "fP < 0.05 vs. VAGX. 
DISCUSSION 
The purpose of this study was to determine if activa- 
tion of pancreatic sympathetic nerves can contribute to 
increased glucagon secretion during insulin-induced 
hypoglycemia. The surgical interventions of vagotomy, 
adrenalectomy, and pancreatic denervation were em- 
ployed to successively eliminate the autonomic inputs 
to the pancreas. The addition of pancreatic denervation 
to the adrenalectomy and vagotomy significantly re- 
duced the glucagon secretory response, demonstrating 
that pancreatic sympathetic nerves can contribute to 
increased glucagon secretion during severe hypoglyce- 
mia in anesthetized dogs. 
The existence of nerve fibers in the pancreatic islets 
was first described by Langerhans in 1869 (27). In 1973 
Porte et al. (35) demonstrated inhibition of insulin 
secretion and Marliss et al. (28) demonstrated stimula- 
tion of glucagon secretion during electrical stimulation 
of the sympathetic innervation to the pancreas. These 
I GLUCOSE INFUSION 
1000 
D 
0 30 60 90 120 
MINUTES 
Fig. 3. The change of pancreatic norepinephrine spillover (APNESO) 
before and after insulin injection and during posthypoglycemia 
glucose infusion in dogs with VAGX (n = 9; q ), dogs with VAGX + 
ADX (n = 10; l ), and dogs with VAGX + ADX + NERVX (n = 6; +). 
findings have been confirmed by a number of other 
investigators (3, 11). Thus it has been hypothesized 
that activation of the pancreatic sympathetic nerves 
with its resulting changes of islet hormone secretion 
could contribute to increased hepatic glucose produc- 
tion during physiological stress (30, 36). Activation of 
the pancreatic sympathetic nerves during stress was 
directly demonstrated in 1988 by measuring increased 
spillover of NE into the pancreatic venous effluent of 
anesthetized dogs during central neuroglucopenic stress 
induced by 2-deoxy-D-glucose (25). These nerves are 
also activated during insulin-induced hypoglycemia 
and release both NE and the sympathetic neuropeptide 
galanin in dogs (19). Although one early study sug- 
gested that the pancreatic sympathetic nerves can 
inhibit insulin secretion during hypoglycemia in dogs 
(31), the present data indicate a role for these nerves to 
stimulate glucagon secretion during severe hypoglyce- 
mia. However, it remains to be demonstrated that 
pancreatic sympathetic nerves have a role in stimulat- 
ing glucagon secretion during more moderate hypogly- 
cemia in the absence of anesthesia, vagotomy, and 
adrenalectomy. 
There are several potential reasons why such a role 
for the pancreatic sympathetic nerves has been difficult 
to demonstrate. First, hypoglycemia itself might di- 
rectly stimulate glucagon secretion (32, 41). Second, 
although activation of the autonomic nervous system 
as a whole has been demonstrated to mediate the 
majority of the increase of hypoglycemia-induced gluca- 
gon secretion in several species (4, 6, 7, 9, 17, 26), 
hypoglycemia activates three different inputs to the 
pancreas (for review see Ref. 23). Third, parasympa- 
thetic or sympathoadrenal activation can act redun- 
dantly to increase glucagon release during hypoglyce- 
mia (22), leading to an underestimation of the autonomic 
contribution when the pancreatic input from only one of 
these major subdivisions of the autonomic nervous 
system is blocked or ablated. The sympathoadrenal 
input consists of two distinct components: 1) adrenal 
medullary epinephrine and 2) the direct sympathetic 
innervation of the pancreas. Investigation of the indi- 
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Table 2. Plasma glucagon and pancreatic glucagon output before and during hypoglycemia 
pg/ml 
Treatment n IRGFA IRGSPDV BFSPDV, ml/min IRG Output, pg/min 
VAGX 
Baseline 
During IIH 
A 
VAGX + ADX 
Baseline 
During IIH 
A 
VAGX + ADX + NERVX 
Baseline 
During IIH 
A 
9 
2523 
53-+12 
+28+12* 
10 
36+3 
56+8 
+20+5* 
6 
33+4 
3424 
+1-+2"1- 
7028 10.0 + 1.1 260-t-40 
372283 10.12 1.3 1,730?380 
+302+81* +O.l k 1.0 + 1,470-+370"" 
164+51 
298258 
+134+54*? 
85214 
15Ot-81 
+65-+73j- 
10.5kO.8 
10.721.3 
+0.2 2 1.4 
8.OkO.9 
6.720.8 
-1.3 50.2" 
760-+270 
1,570*370 
+810?200* 
240270 
450t310 
+210+28Oj- 
Values during hypoglycemia are means k SE, 45-60 min postinsulin injection; n, no. of dogs. IRG, immunoreactive glucagon. *P < 0.05 vs. 
baseline; tP -=c 0.025 vs. VAGX. 
vidual roles of these two components in mediating adrenal medulla to prevent marked hypoglycemia (-30 
changes of pancreatic hormone secretion requires dis- mg/dl) from progressing to severe hypoglycemia (-15 
Crete surgical procedures, specifically adrenalectomy or mg/dl). In a previous study, we found that prevention of 
adrenal demedullation and pancreatic denervation. the glucagon response to hypoglycemia with a somato- 
These interventions have not been previously employed statin infusion also allows insulin to produce glucose 
to examine the potential contribution of the direct nadirs of - 15 mg/dl(l9), despite a plasma Epi response 
sympathetic innervation, independent from the adre- equal to that of control animals. This suggests a role for 
nal medulla, to increased glucagon secretion during increased pancreatic glucagon secretion to prevent 
hypoglycemia. marked hypoglycemia (-30 mg/dl) from progressing to 
In the present study the interventions of adrenalec- 
tomy or adrenalectomy plus pancreatic denervation 
severe hypoglycemia (-15 mg/dl). Taken together, the 
had prominent effects on plasma glucose levels. Base- 
results of the present study and our previous work (19) 
line plasma glucose was lower in VAGX + ADX and 
indicate that both an intact Epi response and an intact 
VAGX + ADX + NERVX dogs, suggesting that adrenal 
glucagon response to hypoglycemia are required to 
Epi and/or glucocorticoids may have been supporting 
prevent marked insulin-induced hypoglycemia from 
hepatic glucose production in these animals. The plasma 
progressing to severe and potentially life-threatening 
glucose levels after insulin administration were also 
levels, and that either response alone is not sufficient to 
lower in the VAGX + ADX and VAGX + ADX + NERVX 
prevent the further decline of plasma glucose levels. 
animals. This lower nadir occurred despite a significant 
Hypoglycemia in the VAGX dogs produced a large 
increase of glucagon secretion observed in the VAGX + 
increase of plasma Epi levels which, as expected, was 
ADX dogs. This result by itself suggests a role for the 
completely abolished by bilateral adrenalectomy in the 
VAGX + ADX and VAGX + ADX + NERVX dogs. 
INSULIN 
INJECTION T-f 
Baseline and hypoglycemic pancreatic NE output was 
also lower in the VAGX + ADX + NERVX dogs, in this 
case because of the surgical disruption of the postgangli- 
onic sympathetic neural pathway. Hypoglycemia in- 
creased pancreatic NE spillover in the dogs with va- 
gotomy alone demonstrating significant activation of 
pancreatic noradrenergic nerves. This contrasts with 
our previous observations that a similar degree of 
hypoglycemia (-30 mg/dl) did not produce measurable 
1 
I  1 I  
30 60 90 120 
pancreatic sympathetic activation in nonvagotomized 
MINUTES 
animals (19). A possible explanation for the discrepancy 
- - is that parasympathetic activity is known to suppress 
I  
0 
Pancreatic NE output was affected by adrenalectomy, 
surgical denervation of the pancreas, and perhaps even 
vagotomy. For example, baseline pancreatic NE output 
was lower in the VAGX + ADX group than in the dogs 
D with VAGX alone. Such a reduction may be due to the 
2 P absence of Pa-adrenergic facilitation of neuronal NE 
5 release secondary to the loss of circulating Epi (37). 
Fig. 4. The change of pancreatic glucagon output before and after 
insulin injection and during posthypoglycemia glucose infusion in 
sympathetic &vity via a presynaptic action of acetyl- 
dogs with VAGX (n = 9; q ), VAGX + ADX (n = 10; a), and dogs with choline to inhibit NE release from noradrenergic nerves 
VAGX + ADX + NERVX (n = 6; a>. (34, 40). Such presynaptic cholinergic inhibition of NE 
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release would not be likely to occur in dogs with prior 
surgical vagotomy, and therefore vagotomy might allow 
significant activation of pancreatic sympathetic nerves 
at a less severe degree of hypoglycemia. 
Both pancreatic glucagon output and arterial plasma 
glucagon levels increased markedly during insulin- 
induced hypoglycemia in VAGX dogs, and these re- 
sponses were not significantly affected by the addition 
of adrenalectomy. When activation of pancreatic sympa- 
thetic nerves was prevented by surgical denervation of 
the pancreas, in addition to vagotomy and adrenalec- 
tomy, neither arterial plasma glucagon nor pancreatic 
glucagon output increased significantly during hypogly- 
cemia. Therefore, in the absence of parasympathetic 
and adrenal medullary activation, pancreatic sympa- 
thetic nerves can make a substantial contribution to 
increased glucagon secretion during severe insulin- 
induced hypoglycemia in halothane-anesthetized dogs. 
However, the data also suggest that factors other than 
activation of pancreatic sympathetic nerves are capable 
of stimulating glucagon secretion during hypoglycemia. 
For example, at 15 and 30 min after insulin injection, 
when the plasma glucose level is still falling, pancreatic 
glucagon output increases in the VAGX + ADX animals 
before a detectable increase of pancreatic NE output. 
This may be due to a lack of sensitivity of the NE output 
measurements to detect early activation of pancreatic 
sympathetic nerves (see RESEARCH DESIGN AND METH- 
ODS). Alternatively, this early increase of glucagon 
secretion may reflect an effect of high levels of exog- 
enous insulin to suppress endogenous insulin secretion 
and release the A cell from paracrine inhibition by 
intra-islet insulin. However, the expected early gluca- 
gon response is absent in the VAGX + ADX + NERVX 
group, perhaps because either an intact neural input or 
adrenal medullary Epi secretion is necessary for this 
indirect effect of exogenous insulin to increase glucagon 
secretion to occur. Nonetheless, later during the hypo- 
glycemic period there is a clear contribution of the 
pancreatic sympathetic nerves to the increase of gluca- 
gon secretion. 
To our knowledge this is the first demonstration of a 
role for the direct sympathetic innervation of the 
pancreas to increase glucagon secretion during hypogly- 
cemic stress. It has now been reported that pancreatic 
NE spillover at euglycemia is larger and that there is a 
marked increase of pancreatic NE spillover (6-fold) 
during less severe hypoglycemia (36 ? 2 mg/dl) in 
conscious dogs (12) than previously described in anes- 
thetized dogs (19). Thus pancreatic sympathetic nerves 
are activated during less severe hypoglycemia in the 
absence of anesthesia-surgery in conscious dogs. How- 
ever, further experiments in conscious animals are 
required to determine if pancreatic sympathetic nerves 
can contribute to increased glucagon secretion during 
moderate hypoglycemia. 
Adrenalectomy without pancreatic denervation did 
not significantly reduce glucagon responses to hypogly- 
cemia, indicating that, under these conditions, Epi by 
itself does not mediate a large portion of the glucagon 
response. Although pancreatic denervation, without 
adrenalectomy was not performed in the present experi- 
mental series, it is likely that in the absence of pancre- 
atic sympathetic neural activation, Epi could contrib- 
ute significantly to the glucagon response, as suggested 
by one previous study (42) and our preliminary data. 
Thus, in vagotomized animals, adrenal Epi and the 
pancreatic sympathetic nerves could function in a 
redundant manner to mediate the glucagon response to 
hypoglycemia. Accordingly, adrenalectomy and pancre- 
atic denervation together eliminated -85% of the in- 
crease of pancreatic glucagon secretion observed in 
animals with vagotomy alone. This result supports the 
findings of a number of other studies that concluded 
that activation of the autonomic nervous system, and 
not hypoglycemia per se, mediates the majority of 
increased glucagon secretion during insulin-induced 
hypoglycemia (for review see Ref. 24). 
In summary, these studies demonstrate that activa- 
tion of the sympathetic innervation of the pancreas can 
contribute to increased glucagon secretion during se- 
vere hypoglycemic stress. Thus activation of pancreatic 
sympathetic nerves via increased glucagon secretion 
may participate in the neuroendocrine counterregula- 
tory response to severe hypoglycemia. 
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